29.05.2024 - WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B .
WARMINSTER, Pa., May 22, 2024 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with.
Arbutus to Participate in Two Upcoming Investor Conferences wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001.
WARMINSTER, Pa., May 02, 2024 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with.